China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)”) is pleased to announce that the ChinaAMC Franklin HK-US Equity Cash Flow Focus ETF and the ChinaAMC Franklin FTSE Innovative Drugs ETF (collectively, the “Funds”) were successfully listed today on the Hong Kong Stock Exchange. Developed in collaboration with Franklin Templeton and issued and managed by ChinaAMC (HK), the Funds broaden the range of cross-market exposures available to investors while reinforcing Hong Kong’s role as a bridge between Chinese and global capital markets.
The listings mark the first product milestone between China Asset Management Co., Ltd. (“ChinaAMC”), the parent company of ChinaAMC (HK), and Franklin Templeton, centered on China-U.S. and China-global invest- ment themes. Combining ChinaAMC (HK)’s established ETF platform and product development capabilities with Franklin Templeton’s global ETF expertise and research platform, the Funds bring together two comple- mentary themes: resilient cash-generating businesses positioned to navigate uncertain markets and innova- tive pharmaceutical firms at the forefront of R&D-led healthcare advancements.